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Abstract KOR-3 chimeras were constructed in which the first splice variant of KOR-3 [12,13]. In these studies, six antisense 
coding exon of KOR-3 was exchanged for the corresponding first oligodeoxynucleotide probes targeting the second and third 
coding exon of either MOR-1 (MOR-1/KOR-3) or DOR- I  coding exons of KOR-3 blocked ~c3 analgesia. However, an 
(DOR-1/KOR-3). All three clones were expressed in CHO cells additional five probes based upon the first coding exon were 
and characterized with regards to their binding profiles for inactive, raising the possibility that the ~:3 receptor might have 
orphanin FQ/nociceptin (OFQ/N) and a variety of opioids as an alternatively spliced first coding exon. To determine 
well as their functional activities in cyclase studies, whether changes in the first coding exon of KOR-3 might 
12SI[Tyrl4]OFQ/N labels both KOR-3 (Ko 37 pM) and the influence the binding and functional characteristics of the re- 
MOR-1/KOR-3 chimera (K1) 39 pM) equally well. Although its ceptor, we generated chimeras by exchanging the first coding 
affinity for the DOR-1/KOR-3 chimera is quite good (KD 135 exon of KOR-3 with the corresponding first coding exon from 
pM), it is slightly lower than the other two. Competition studies 
confirm the high affinity of OFQ/N for all three clones, a traditional mu (MOR-1) or delta (DOR-1) opioid receptor 
However, several competitors clearly distinguish the chimeras and examined receptor binding and function. 
from KOR-3. OFQ/N(1-11) competes KOR-3 (Ki 55 nM) over 
6-fold more potently than either of the chimeras (Ki values > 350 2. Materials and methods 
nM). Conversely, the modest affinity of naloxone benzoylhy- 
drazone for KOR-3 (310 nM) is greatly increased in both the 2.1. Materials 
MOR-1/KOR-3 (Ki 69 nM) and DOR-1/KOR-3 (Ki 74 nM) Restriction enzymes were purchased from Promega (Madison, WI, 
chimeras. The remainder of the opioids tested have no USA). DNA sequencing kits were from Perkin-Elmer (Foster City, 
appreciable affinity against any of the clones. Functionally, CA, USA) and US Biochemicals (Cleveland, OH, USA). OFQ(1-17), 
OFQ/N inhibits forskolin-stimulated cAMP accumulation in [Tyr14]OFQ(1-17), OFQ(1-7), and OFQ(1 11) were synthesized by 
both the KOR-3 and the MOR-1/KOR-3 chimera by almost the Core Protein Facility and purified by HPLC. Morphine sulfate, 
40%, with IC50 values in the low nanomolar ange. Little activity DPDPE, and U50,488 were obtained from the Research Technology 
Branch of the National Institute on Drug Abuse (Rockville, MD). 
is seen against the DOR-1/KOR-3 chimera. Naloxone benzoyl- Naloxone benzoylhydrazone (NalBzoH) was synthesized as described 
hydrazone inhibits cAMP accumulation in the KOR-3 and the previously [16]. Oligodeoxynucleotides w re synthesized by Integrated 
DOR-1/KOR-3 chimera. Although naloxone benzoylhydrazone DNA Technologis, Inc. (Coralville, IO, USA). All other chemicals 
has higher affinity for the MOR-1/KOR-3 chimera in binding and reagents were purchased from Sigma Chemical Co. (St. Louis, 
studies than KOR-3 itself, it is inactive in cyclase studies using MO, USA) unless otherwise noted. 
the MOR-1/KOR-3 chimera, implying that the replacement of 
the first coding exon increases affinity while decreasing intrinsic 2.2. Constructing and expressing the chimeras 
activity. The Chimeras were constructed by using an overlapping PCR strat- 
egy. The first coding exon 1 of mouse MOR-1 was amplified in PCR 
using a sense primer A (5'-TGGGTACCGGGCCCCCCC-3') includ- 
Key words." Opioid receptor; Orphanin FQ;  Nociceptin; ing a Kpnl site, located in the vector upstream of the 5' MOR-1 clone 
KOR-3;  OLR1 and an antisense primer which contained 22 bases corresponding to
the 3'-end of the MOR-1 exon 1 and 13 bases corresponding to the 5'- 
end of the KOR-3 exon 2 (5'-CATCTTGGTGTGCCTTACAATCA- 
CATACATGACCA-3'). The template was the mouse MOR-1 con- 
1. Introduction struct [17]. The amplified fragment contained all the coding exon 1 of 
the MOR-1 tailing a 13 bp of KOR-3 exon 2. The second and third 
coding exons were separately amplified using a sense primer which 
A novel peptide, termed orphanin FQ [1] or nociceptin [2] contained 11 bases of the 3'-end of the MOR-1 exon 1 and 20 bases of 
(OFQ/N), recently has been identified which has very high the 5'-end of the KOR-3 exon 2 (5'-GTGATTGTAAGGCACAC- 
affinity for a recently cloned member of the opioid receptor CAAGATGAAGACTG-3') and an antisense B corresponding to 
family [3-11]. We have cloned and characterized both the the nucleotide sequence of the KOR-3 clone [12,13] at position 
mouse homolog of this receptor, KOR-3 [12,13], and its 1420-1438 tailing a XhoI site. The template was the mouse KOR-3 
clone. The PCR fragment included the complete xons 2 and 3 of 
gene [14]. Opioids demonstrate low affinity for this receptor KOR-3 capping a 11 bp of the MOR-1 exon 1. The chimera contain- 
and inhibit adenylyl cyclase activity only at high concentra- ing the MOR-1 exon 1 and KOR-3 exon 2 and 3 (MOR-1/KOR-3) 
tions [8,12,13]. However, other approaches have implied a (Fig. 1) was produced through PCR by using the mixture of the above 
close association between the receptor encoded by KOR-3 two PCR fragments as templates since the two fragments had 24 bp 
overlapping that was dictated by the above primers. The sense primer 
and the n3 receptor found in brain. In addition to the recog- A and the antisense B were also included in the reaction. The expected 
nition of the expressed KOR-3 clone by a monoclonal anti- PCR product was purified, digested with the KpnI and XhoI and 
body generated against the n3 receptor [15], antisense studies subcloned into the KpnI and XhoI sites of a pcDNA3 (Clontech) 
raise the possibility that the na receptors may represent a expression vector. The clones were sequenced using either Sequenase 
version 2 (USB) or a Amplicyele sequencing kit (Perkin-Elmer) to 
confirm the structure and to ensure the absence of any mutations 
*Corresponding author. Fax: (1) (212) 794-4332. induced by the PCR. The chimera containing the DOR-1 exon 1 
E-mail: pasterng@mskmail.mskcc.org and KOR-3 exons 2 and 3 (DORI/KOR3) (Fig. 1) was generated 
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using the same strategy. The sense primer A and an antisense primer MOR-I MORI/KOR3 
w e us  
to amplify the DOR-1 exon 1, and the antisense B and a sense primer 
(5'-GGCATCGTCCGGCACACCAAGATGAAGACTG-3') to am- KOR-3 
plify the KOR-3 exon 2 and 3. Both constructs were translated into ~ -  
proteins with the predicted molecular weight in a in vitro transcription 
coupled in vitro translation system (Novagen) (data not shown). t-.._., DOR-I ','...-,, DOR1/KOR3 
The resulting MORI/KOR3 and DORI/KOR3 constructs and the ,::'.:'~ .... 
KOR-3 clone in pcDNA3 were transfected into CHO cells using li- 
pofectAMINE reagent (Gibco BRL) and single stable clones selected 
in the presence of G418. 
2.3. Characterization of the chimeras and the KOR-3 constructs 
[Tyr14]OFQ/N was iodinated with Nal2SI using chloramine-T, as Fig. 1. Schematic of KOR-3 and the chimeras. Schematic represen- 
previously described [181. The mixture was applied to a C18 Sep- tation of KOR-3 (light lines) and the chimeras. The exchanged first 
Pak cartridge (Waters, Milford, MA) and the monoiodinated peptide exons from MOR-1 and DOR-1 are denoted by a heavy line. 
separated with a step gradient. The radiochemical purity (> 95%) of 
the iodinated peptide was confirmed by reverse-phase high-perform- 
ance liquid chromatography (rpHPLC). There was no detectable 
di-iodo compound in the purified material. [12SlI[Tyrlg]OFQ/N bind- lower, as anticipated based upon the saturation studies. OFQ/ 
ins was conducted inKPO4 buffer (10 raM, pH 7.0) containing MgCle N(1-7) and OFQ/N(1-11) represent potential peptides which 
(5 raM), bacitracin (0.25 mg/ml) and bovine serum albumin (BSA, could be generated from OFQ/N, a possibility supported by 
0.1%) with washed membranes from the indicated clones. Samples their pharmacological ctivity in mice [23,24]. Although OFQ/ 
were incubated for 60 rain at 25°C. After incubation, the membranes N(I-11) labels the native KOR-3 receptor easonably well (Ki 
were pelleted in a microcentrifuge and counted in a Packard Cobra II 
Automated Gamma counter. Non-specific binding was determined in 55 nM), its affinity for the chimeras is lowered over 6-fold 
the presence of OFQ/N (1 laM). Specific binding was defined as the (p < 0.03). Conversely, the modest affÉnity of the ~a ligand 
difference in binding between total and non-specific binding. Satura- naloxone benzoylhydrazone (NalBzoH) is increased over 4- 
tion studies were subjected to non-linear regression analysis to deter- fold in the chimeras (p < 0.04). Thus, the relative affinity of 
mine K1) values. Competition studies yielded IC50 values which were OFQ/N(1-11) compared to NalBzoH shifts over 25-fold from 
converted to Ki values as described in the literature [19,20]. 
Adenylyl cyclase activity was assessed by measuring cAMP levels, KOR-3 to the chimeras. Traditional opiates and OFQ/N(1-7) 
as previously reported [21,22]. Briefly, inhibition of forskolin-stimu- all display no appreciable affinity for any of the three recep- 
lated cAMP accumulation was assessed in membranes (0.6~0.8 mg tors. 
protein) after a 10 rain incubation at 37°C in the presence of (0.5 We also examined the ability of OFQ/N to inhibit forsko- 
laM), the phosphodiesterase inhibitor RO-20 and various concentra- 
tions of agonists. The assay was stopped by boiling the samples for lin-stimulated cAMP accumulation in the three cell lines. 
5 min, after which they were centrifuged at 1000×g for 10 min and OFQ/N inhibits cAMP accumulation i  the KOR-3 cells by 
the supernatant assayed for cAMP levels. The amount of cAMP pres- nearly 40%, with an ICs0 less than 1 nM (Fig. 2), results 
ent was calculated from a standard curve determined with unlabeled similar to those previously reported with homologous clones 
cAMP and the inhibition determined. [1,2]. Although OFQ/N inhibits cAMP accumulation to the 
same degree in the MOR-1/KOR-3 chimera, higher doses are 
3. Results needed to achieve these effects. The effects of OFQ/N in the 
DOR-1/KOR-3 chimera are limited at concentrations under 
First, we examined 125I[Tyr14]OFQ/N binding in CHO cells 100 nM and are not significantly different from values in non- 
stably transfected with KOR-3 or the two chimeras (Fig. 1). transfected CHO cells. 
All three cell lines bind 125I[Tyr14]OFQ/N quite potently. Sat- NalBzoH inhibits cAMP accumulation i the KOR-3 cells, 
uration studies reveal that 125I[Tyr14]OFQ/N labels the KOR- consistent with prior observations [12,13]. NalBzoH also in- 
3 cells with an affinity (KD 37 pM) (Table 1) which is similar hibits cAMP accumulation i the DOR-1/KOR-3 chimera to 
to that reported previously with an homologous clone [1]. The the same degree and slightly more potently than in the KOR-3 
MOR-1/KOR-3 chimera shows no change in its affinity for cells, consistent with its 4-fold greater binding affinity (Fig. 3). 
125I[Tyr14]OFQ/N, while its affinity in the DOR-1/KOR-3 chi- Despite its increased affinity for the MOR-1/KOR-3 chimera 
mera is lowered slightly, in binding assays, NalBzoH is inactive at all concentrations 
Competition studies confirm the unique selectivities of the tested in the cyclase assays and antagonizes OFQ/N. 
KOR-3 clone and the chimeras (Table 2). Both OFQ/N and 
[Tyra4]OFQ/N potently compete binding in all three clones, 4. Discussion 
although its affinity for the DOR-1/KOR-3 chimera is slightly 
Chimera studies must be interpreted cautiously due to the 
extensive conformational changes which can result from the 
Table 1 exchange of such a large region. Nevertheless, the effects of 
a25I[Tyr14]OFQ/N binding sites in CHO cells transfected with the 
KOR-3 and chimeric receptor clones substituting exon 1 from a traditional opioid receptor with 
that in KOR-3 yields interesting results. This study confirms 
Clone KD (pM) Bmax (fmol/mg protein) the high affinity of OFQ/N for the mouse homologue of the 
KOR-3 36.7+ 1.6 17.3 orphan receptor, KOR-3, along with its expected selectivity 
MOR- 1/KOR-3 39.4 _+ 1.4 7.1 
DOR-1/KOR-3 135_+ 5.7 3.8 profile for opioids and OFQ/N. Both chimeras maintain high 
affinity for OFQ/N with only a small decrease in affinity in the 
Saturation studies were performed with 125I[Tyra4]OFQ/N on CHO 
cells transfected with the indicated clone. Binding was best fitted by a DOR-1/KOR-3 chimera compared to KOR-3. Prior work 
one-site model. Values are the means _+ S.E.M. of three independent from our laboratory has revealed a complex behavioral phar- 
determinations, macology for OFQ/N and its fragments [23,24]. In these stud- 
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Fig. 2. Effects of OFQ/N on cAMP accumulation in transfected Fig. 3. Effects of NalBzoH on cAMP accumulation i  transfected 
CHO cells. The ability of OFQ/N at the stated concentrations to in- CHO cells. The ability of NalBzoH at the stated concentrations to
hibit forskolin-stimulated cAMP accumulation was determined in inhibit forskolin-stimulated cAMP accumulation was determined in 
CHO cells transfected with KOR-3, MOR-1/KOR-3, or DOR-1/ CHO cells transfected with KOR-3, MOR-1/KOR-3 or DOR-I/ 
KOR-3, as described in Section 2. KOR-3, as described in Section 2. 
ies, OFQ/N(1-11) produces a potent, naloxone-reversible an- cAMP accumulation in the DOR-1/KOR-3 chimera and is 
algesia implying that it, too, may be physiologically relevant, inactive against the MOR-1/KOR-3 chimera. This loss of in- 
OFQ/N(1 11) shows reasonable affinity for KOR-3, but its trinsic activity is interesting. NalBzoH is an effective ~;3 ago- 
affinity is lowered 6-10-fold in the chimeras. Thus, it is inter- nist in cyclase assays [21,22], but it is an antagonist at mu 
esting that the binding affinity of OFQ/N(1-11) can be dis- receptors [25]. Substituting the first coding exon of MOR-1 
sociated from OFQ/N. eliminates the efficacy of NalBzoH without affecting its affi- 
Despite the close relationship between KOR-3 and the ~3 nity. Thus, these chimeras illustrate the ability to change the 
receptor, they are likely distinct receptors, possibly splice var- affinity of OFQ/N(1-11) and NalBzoH in opposite directions 
iants [12,13]. Their relationship is further supported by the and demonstrate that changes in affinity can be dissociated 
NalBzoH studies. NalBzoH has only a modest binding affinity from intrinsic activity. 
against KOR-3. Replacing the first coding exon enhances this 
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